After a year of controversy and complaints, Sen. Elizabeth Warren is asking a federal watchdog to investigate GSK over its ...

Something seems to be going awry with GlaxoSmithKline's game plan for its respiratory franchise, with new products positioned ... increasing competition in the asthma and chronic obstructive ...

"Simultaneous regulatory submissions for two indications highlight our confidence in depemokimab to help reduce the burden of both asthma ... products. It is one of five key product launches that ...

GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.31 billion and an impressive gross profit margin of 72.39%, has announced that its new drug ...

Patients with asthma who used depemokimab tolerated treatment well while experiencing reductions in rates of clinically ...

The U.S. Food and Drug Administration (FDA) has accepted GlaxoSmithKlines (NYSE:GSK) biologics license application for ...

GSK's long-acting asthma drug halved attacks in phase 3, backing up blockbuster hopes “Today’s data build on the body of evidence supporting depemokimab as an ultra-long-acting treatment and ...

In the US, asthma affects over ... National Medical (TASE:BLWV) Products Administration, following positive phase III trial results. These developments reflect GSK’s ongoing efforts to advance ...

GSK's revenue and EPS exceeded my expectations ... with a frequency of use only once every six months for the treatment of asthma and CRSwNP [chronic rhinosinusitis with nasal polyps], and ...

The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for depemokimab for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps ...